140 related articles for article (PubMed ID: 21113923)
1. Comparison of BD Surepath and ThinPrep Pap systems in the processing of mucus-rich specimens.
Kenyon S; Sweeney BJ; Happel J; Marchilli GE; Weinstein B; Schneider D
Cancer Cytopathol; 2010 Oct; 118(5):244-9. PubMed ID: 21113923
[TBL] [Abstract][Full Text] [Related]
2. Split-sample analysis of discarded cells from liquid-based Pap smear sampling devices.
Rinas AC; Mittman BW; Le LV; Hartmann K; Cayless J; Singh HK
Acta Cytol; 2006; 50(1):55-62. PubMed ID: 16514841
[TBL] [Abstract][Full Text] [Related]
3. Reprocessing unsatisfactory ThinPrep papanicolaou tests using a modified SurePath preparation technique.
Randolph ML; Wu HH; Crabtree WN
Cancer Cytopathol; 2014 May; 122(5):343-8. PubMed ID: 24940587
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the SurePath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study.
Fremont-Smith M; Marino J; Griffin B; Spencer L; Bolick D
Cancer; 2004 Oct; 102(5):269-79. PubMed ID: 15386329
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effectiveness of two liquid-based Papanicolaou systems in the handling of adverse limiting factors, such as excessive blood.
Sweeney BJ; Haq Z; Happel JF; Weinstein B; Schneider D
Cancer; 2006 Feb; 108(1):27-31. PubMed ID: 16302249
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the ThinPrep Pap test in clinical practice. A seven-month, 16,314-case experience in northern Vermont.
Papillo JL; Zarka MA; St John TL
Acta Cytol; 1998; 42(1):203-8. PubMed ID: 9479341
[TBL] [Abstract][Full Text] [Related]
7. Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance Papanicolaou results in SurePath and ThinPrep specimens.
Siddiqi A; Spataro M; McIntire H; Akhtar I; Baliga M; Flowers R; Lin E; Guo M
Cancer; 2009 Oct; 117(5):318-25. PubMed ID: 19693966
[TBL] [Abstract][Full Text] [Related]
8. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
[TBL] [Abstract][Full Text] [Related]
9. ThinPrep versus conventional Papanicolaou smear in the cytologic follow-up of women with equivocal cervical smears.
Negri G; Menia E; Egarter-Vigl E; Vittadello F; Mian C
Cancer; 2003 Dec; 99(6):342-5. PubMed ID: 14681941
[TBL] [Abstract][Full Text] [Related]
10. The ThinPrep Pap test. A review of clinical studies.
Linder J; Zahniser D
Acta Cytol; 1997; 41(1):30-8. PubMed ID: 9022723
[TBL] [Abstract][Full Text] [Related]
11. Performance of the CellSolutions Glucyte liquid-based cytology in comparison with the ThinPrep and SurePath methods.
Alaghehbandan R
Acta Cytol; 2013; 57(2):189-97. PubMed ID: 23407055
[TBL] [Abstract][Full Text] [Related]
12. Clinical results of a split sample liquid-based cytology (ThinPrep) study of 4,322 patients in a Turkish institution.
Tuncer ZS; Başaran M; Sezgin Y; Firat P; Mocan Kuzey G
Eur J Gynaecol Oncol; 2005; 26(6):646-8. PubMed ID: 16398228
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
[TBL] [Abstract][Full Text] [Related]
14. Increased detection of epithelial cell abnormalities by liquid-based gynecologic cytology preparations. A review of accumulated data.
Austin RM; Ramzy I
Acta Cytol; 1998; 42(1):178-84. PubMed ID: 9479337
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of liquid-based Pap tests: comparison of concurrent liquid-based tests and cervical biopsies on 782 women with previously abnormal Pap smears.
Guo M; Hu L; Martin L; Liu S; Baliga M; Hughson MD
Acta Cytol; 2005; 49(2):132-8. PubMed ID: 15839615
[TBL] [Abstract][Full Text] [Related]
16. Morphologic analysis of false negative SurePath® slides using Focalpoint™ GS computer-assisted cervical screening technology: An Australian experience.
Bowditch RC; Clarke JM; Baird PJ; Greenberg ML
Diagn Cytopathol; 2015 Nov; 43(11):870-8. PubMed ID: 26174002
[TBL] [Abstract][Full Text] [Related]
17. Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates.
Rozemeijer K; Penning C; Siebers AG; Naber SK; Matthijsse SM; van Ballegooijen M; van Kemenade FJ; de Kok IM
Cancer Causes Control; 2016 Jan; 27(1):15-25. PubMed ID: 26458884
[TBL] [Abstract][Full Text] [Related]
18. Laboratory implementation and efficacy assessment of the ThinPrep cervical cancer screening system.
Bolick DR; Hellman DJ
Acta Cytol; 1998; 42(1):209-13. PubMed ID: 9479342
[TBL] [Abstract][Full Text] [Related]
19. Liquid-based cytology: evaluation of effectiveness, cost-effectiveness, and application to present practice.
Cox JT
J Natl Compr Canc Netw; 2004 Nov; 2(6):597-611. PubMed ID: 19780303
[TBL] [Abstract][Full Text] [Related]
20. Test performance comparison of inform HPV and hybrid capture 2 high-risk HPV DNA tests using the SurePath liquid-based Pap test as the collection method.
Davis-Devine S; Day SJ; Freund GG
Am J Clin Pathol; 2005 Jul; 124(1):24-30. PubMed ID: 15923167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
